Syndax Pharmaceuticals Inc [NASDAQ: SNDX] traded at a low on Tuesday, posting a -1.80 loss after which it closed the day’ session at $13.07.
The results of the trading session contributed to over 2733642 shares changing hands. Over the past one week, the price volatility of Syndax Pharmaceuticals Inc stands at 4.39% while the volatility over the past one month is 5.22%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for SNDX stock reached $1.10 billion, with 85.57 million shares outstanding and 81.08 million shares in the current float. Compared to the average trading volume of 1.78M shares, SNDX reached a trading volume of 2733642 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Syndax Pharmaceuticals Inc [SNDX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNDX shares is $37.21 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNDX stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Syndax Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 24, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on June 28, 2024, representing the official price target for Syndax Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $36 to $23, while Scotiabank kept a Sector Perform rating on SNDX stock.
The Average True Range (ATR) for Syndax Pharmaceuticals Inc is set at 0.82, with the Price to Sales ratio for SNDX stock in the period of the last 12 months amounting to 68.47. The Price to Book ratio for the last quarter was 3.05, with the Price to Cash per share for the same quarter was set at 4.65.
How has SNDX stock performed recently?
Syndax Pharmaceuticals Inc [SNDX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.11. With this latest performance, SNDX shares dropped by -18.77% in over the last four-week period, additionally sinking by -34.26% over the last 6 months – not to mention a drop of -37.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNDX stock in for the last two-week period is set at 30.36, with the RSI for the last a single of trading hit 28.37, and the three-weeks RSI is set at 32.75 for Syndax Pharmaceuticals Inc [SNDX]. The present Moving Average for the last 50 days of trading for this stock 17.10, while it was recorded at 13.11 for the last single week of trading, and 19.91 for the last 200 days.
Syndax Pharmaceuticals Inc [SNDX]: Deeper insight into the fundamentals
Syndax Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.99 and a Current Ratio set at 6.99.
Earnings analysis for Syndax Pharmaceuticals Inc [SNDX]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNDX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Syndax Pharmaceuticals Inc go to 23.50%.
Insider trade positions for Syndax Pharmaceuticals Inc [SNDX]
There are presently around $106.50%, or 107.37%% of SNDX stock, in the hands of institutional investors. The top three institutional holders of SNDX stocks are: BLACKROCK INC. with ownership of 7.91 million shares, which is approximately 9.2788%. WELLINGTON MANAGEMENT GROUP LLP, holding 7.34 million shares of the stock with an approximate value of $$150.67 million in SNDX stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $$117.47 million in SNDX stock with ownership which is approximately 6.715%.
